Thyroid effects of TKI treatment in chronic myeloid leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This study looks at how TKI medications, used to treat chronic myeloid leukemia (CML), may affect thyroid function. It will track patients starting TKI therapy to see if thyroid problems develop.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been newly diagnosed with chronic myeloid leukemia (CML) and have the Philadelphia chromosome
- You have not taken any TKI medication before
- You do not have any prior thyroid disease (underactive or overactive thyroid, or autoimmune thyroid condition)
- You are not taking any medications that affect thyroid function (like dexamethasone, phenytoin, carbamazepine, rifampin, or phenobarbital)
- You are not pregnant or breastfeeding, and you are not taking birth control pills or corticosteroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
This study looks at how a type of leukemia treatment called tyrosine kinase inhibitors affects blood sugar and cholesterol levels in people with chronic myeloid leukemia. It may help doctors understand and manage these side effects better.
This study examines whether a new type of cancer medication affects thinking, memory, and focus in people with chronic myeloid leukemia (CML) or chronic lymphocytic leukemia (CLL). Researchers will compare people starting this medication with healthy volunteers to understand any changes.
This study looks at whether people with chronic myeloid leukemia (CML) can safely lower their dose of targeted therapy before completely stopping it. It aims to see if a gradual reduction helps maintain long-term remission without the cancer coming back.
This study looks at whether tyrosine kinase inhibitors (TKIs), a common treatment for chronic myeloid leukemia (CML), are linked to erectile dysfunction in men. It aims to help patients and doctors understand possible side effects.
Hear when a new Leukaemia (Chronic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.